GAVI & R21/Matrix-M

GAVI & R21/Matrix-M

  • Context: 

  • Gavi and UNICEF recently announced a new agreement to make the R21/Matrix-M malaria vaccine significantly more accessible and affordable. 

  • This paves the way for protecting nearly seven million more children over the next five years 

  • R21/Matrix-M Malaria Vaccine: 

  • It was Co-developed by the University of Oxford and Serum Institute of India (SII) 

  • It utilizes Novavax's Matrix-M adjuvant technology 

  • It is the second malaria vaccine pre-qualified by the WHO (after RTS,S/AS01) for children at risk of malaria caused by Plasmodium falciparum.  

  • It has shown to prevent around 75% of malaria episodes when administered seasonally in areas of high transmission 

  • The new deal aims to lower the price to $2.99 per dose, generating significant savings for Gavi and countries 

  • About GAVI, the Vaccine Alliance 

  • It is a global public-private partnership established in 2000 with the aim of increasing equitable access to vaccines in lower-income countries. 

  • Its mission aligns with Primary Health Care (PHC) principles and the Immunization Agenda 2030, focusing especially on zero-dose children (children who have received no routine vaccines). 

  • It brings together governments, WHO, UNICEF, World Bank, civil society, vaccine manufacturers, and private philanthropies (including the Gates Foundation). 

  • Permanent Members: WHO, UNICEF, World Bank, Gates Foundation, The Vaccine Fund. 

  • Headquartered in Geneva. 

  • Gavi aims to vaccinate at least 500 million children between 2026 and 2030, potentially saving over 8 million lives and generating $100 billion in economic benefits. 

  • Gavi’s Strategic Framework (Gavi 5.0: 2021–25) 

  • The vision of leaving no one behind with immunization is aligned with the Sustainable Development Goals (SDGs) and Immunization Agenda 2030 (IA2030) 

  • The core principle is equity. 

  • It is the organizing principle with a specific focus on reaching zero-dose children (those who have not received a single routine vaccine shot) and missed communities. 

  • Governance Structure: 

  • The Board:  

  • The supreme decision-making body that sets strategic direction and policy.  

  • It includes permanent seats for core partners and rotating seats for governments and industry. 

  • The Executive Committee acts on behalf of the Board between meetings to handle urgent operational issues. 

  • The Secretariat is based in Geneva 

  • It manages day-to-day operations and program implementation. 

  • Task Forces:  

  • These are specialized groups formed to address complex, specific challenges like vaccine financing.